Supreme Court To Consider What Adverse Events Pharma Must Report To Avoid Securities Suits
This article was originally published in The Pink Sheet Daily
Executive Summary
The court will decide whether companies can be sued for failing to disclose adverse event reports that are not statistically significant; the case before the court involves Matrixx's Zicam Cold Remedy products.
You may also be interested in...
Adverse Event Disclosure Standards Could Be Altered By Supreme Court In Matrixx Case
Supreme Court justices appeared skeptical of Matrixx Initiatives’ insistence that companies need not tell investors about reports of drug adverse events unless they are statistically significant, suggesting the court may set a different disclosure standard for a securities fraud suit.
Adverse Event Disclosure Standards Could Be Altered By Supreme Court In Matrixx Case
Supreme Court justices appeared skeptical of Matrixx Initiatives’ insistence that companies need not tell investors about reports of drug adverse events unless they are statistically significant, suggesting the court may set a different disclosure standard for a securities fraud suit.